01—Abstract
Summary
Summary of the 10-K filed February 21, 2014. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc. completed its first full year as an independent, publicly traded company in 2013, reporting a 2% increase in net sales to $18.8 billiona.
This growth was primarily driven by strong performance from its flagship product, HUMIRA, which accounted for 57% of total sales, and positive contributions from other key products like Synthroid and Creon. The company successfully navigated the loss of exclusivity for its lipid franchise due to generic competition, which negatively impacted revenue by $1.1 billionb, but offset this through disciplined cost management and operational efficiencies. AbbVie also maintained a strong balance sheet, generating $6.3 billion in cash flow from operations, enabling it to invest in its robust pipeline and return capital to shareholders through dividends.
The company continues to focus on expanding HUMIRA's indications and market reach, alongside advancing over 20 compounds in its development pipeline across critical therapeutic areas, positioning itself for future growth. Key risks for investors revolve around the potential impact of HUMIRA's patent expiration in December 2016 and the ensuing competition from biosimilars. AbbVie's reliance on HUMIRA represents a significant concentration of revenue, making its market exclusivity a critical factor for future performance.
The company is also actively managing its R&D pipeline, with substantial investments in areas like immunology, virology, and oncology, but the inherent uncertainties in drug development mean that pipeline success is not guaranteed. Additionally, regulatory changes, pricing pressures, and the competitive landscape for pharmaceuticals remain ongoing challenges.
02—Key points
Key Highlights
- AbbVie reported 2013 net sales of $18.8 billion, a 2% increase year-over-year, primarily driven by HUMIRA.
- HUMIRA was the company's top-selling product, accounting for 57% of total sales ($10.7 billion).
- The company experienced a $1.1 billion revenue loss from its lipid franchise due to generic competition.
- AbbVie generated strong cash flow from operations of $6.3 billion in 2013.
- The company continued to invest heavily in R&D, spending $2.9 billion, and maintained a pipeline of over 20 compounds in Phase II or III development.
- AbbVie paid $2.6 billion in cash dividends to shareholders in 2013.
- The key patent for HUMIRA in the U.S. is set to expire in December 2016, posing a future risk.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2013, AbbVie Inc. kept $0.22.
- Revenue$18.79B100.0%
- Cost of revenue−$4.58B24.4%
- Gross profit$14.21B75.6%
- Operating costs−$8.54B45.5%
- Operating income$5.66B30.1%
- Interest, other & tax−$1.54B8.2%
- Net income$4.13B22.0%
Where FY2013 revenue went
$18.79B- SG&A: $5.35B, 28% of revenue
- Cost of revenue: $4.58B, 24% of revenue
- Net income: $4.13B, 22% of revenue
- Other operating costs: $3.19B, 17% of revenue
- Interest, other & tax: $1.54B, 8.2% of revenue
Kept 22% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2013filed February 21, 2014Financial Statements
FY2013 against FY2012
| Line item | FY2013FY2012 | Change |
|---|---|---|
| Revenue | $18.79B$18.38B | +2.2% |
| Cost of Revenue | $4.58B$4.51B | +1.6% |
| Gross Profit | $14.21B$13.87B | +2.4% |
| SG&A Expenses | $5.35B$4.99B | +7.3% |
| Operating Expenses | $13.13B$12.56B | +4.5% |
| Operating Income | $5.66B$5.82B | −2.6% |
| Interest Expense | $299.00M$104.00M | +187.5% |
| Net Income | $4.13B$5.28B | −21.7% |
| EPS (Basic) | $2.58$3.35 | −23.0% |
| EPS (Diluted) | $2.56$3.35 | −23.6% |
| Shares Outstanding (Basic) | 1.59B1.58B | +0.8% |
| Shares Outstanding (Diluted) | 1.60B1.58B | +1.7% |
05—Questions
Frequently Asked Questions
What was AbbVie's primary growth driver in 2013?
AbbVie's primary growth driver in 2013 was HUMIRA, its flagship biologic therapy. HUMIRA's sales increased by 15% globally, reaching $10.7 billion and constituting 57% of AbbVie's total net sales for the year.
What are the main risks highlighted in the filing regarding AbbVie's future performance?
The most significant risk highlighted is the upcoming expiration of the U.S. composition of matter patent for HUMIRA in December 2016. This expiration could lead to increased competition from biosimilars or generic versions, potentially impacting AbbVie's revenue and profitability, given HUMIRA's substantial contribution to overall sales. Additionally, AbbVie's reliance on its R&D pipeline for future growth carries inherent uncertainties associated with drug development.
How did AbbVie manage the loss of revenue from its lipid franchise?
AbbVie experienced a $1.1 billion revenue loss from its lipid franchise (TriCor, TRILIPIX, Niaspan) due to the introduction of generic competition starting in late 2012 and throughout 2013. The company managed this by focusing on its strong-selling products like HUMIRA and maintaining operational efficiencies to offset the impact on overall financial performance.
What is AbbVie's strategy for future growth?
AbbVie's strategy for future growth centers on maximizing its existing portfolio through new indications and geographic expansion, particularly for HUMIRA. It also emphasizes advancing its R&D pipeline, which includes over 20 compounds in late-stage development, and making strategic investments and collaborations to bring innovative therapies to market.
06—Continue